Skip to main content

Table 2 Unadjusted and sequentially multivariable adjusted risk of principal outcomes in ET and PV patients associated to hs-CRP and PTX-3 values over their respective medians

From: Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera

 

Hs-CRP ≥0.8 mg/La

PTX-3 ≥4.8 ng/mLa

 

OR

95% CI

p

OR

95% CI

p

Thrombosis (n = 55)

 Unadjusted

2.57

1.39–4.75

0.003

0.66

0.37–1.16

0.145

 Adjusted for

  + Male sex

2.57

1.39–4.75

0.003

0.66

0.37–1.16

0.146

  + Age at diagnosis

2.56

1.38–4.73

0.003

0.65

0.37–1.15

0.139

  + PV disease

2.59

1.40–4.81

0.003

0.60

0.34–1.07

0.085

  + Cytoreduction + antiplatelet agents

2.60

1.37–4.95

0.003

0.57

0.31–1.04

0.068

  + JAK2V617F homo

2.60

1.37–4.95

0.003

0.57

0.31–1.04

0.066

Bleeding (n = 43)

 Unadjusted

0.77

0.41–1.45

0.419

1.07

0.57–2.02

0.831

 Adjusted for

  + Male sex

0.77

0.41–1.46

0.428

1.07

0.57–2.01

0.842

  + Age at diagnosis

0.84

0.44–1.61

0.596

1.06

0.56–2.01

0.864

  + PV disease

0.84

0.44–1.62

0.603

0.97

0.50–1.86

0.920

  + Cytoreduction+

antiplatelet agents

0.82

0.43–1.59

0.557

0.95

0.49–1.84

0.883

  + JAK2V617F homo

0.83

0.43–1.60

0.574

0.92

0.48–1.79

0.815

Haematological evolution (n = 33)

 Unadjusted

2.70

1.23–5.95

0.013

1.84

1.02–3.96

0.044

 Adjusted for

  + Male sex

2.66

1.20–5.86

0.015

1.87

1.02–3.99

0.042

  + Age at diagnosis

2.61

1.18–2.88

0.018

1.84

1.01–3.98

0.046

  + PV disease

2.70

1.21–6.01

0.015

1.59

0.72–3.48

0.251

  + Cytoreduction + antiplatelet agents

2.72

1.21–6.15

0.016

1.64

0.74–3.63

0.225

  + JAK2V617F homo

2.79

1.23–6.32

0.014

1.55

0.69–3.46

0.286

Death (n = 56)

 Unadjusted

3.93

2.01–7.68

<.0001

1.58

1.10–2.84

0.039

 Adjusted for

  + Male sex

3.86

1.98–7.55

<.0001

1.61

1.09–2.85

0.041

  + Age at diagnosis

4.45

2.16–9.15

<.0001

1.56

1.05–2.44

0.042

  + PV disease

4.65

2.24–9.65

<.0001

1.14

0.60–2.17

0.680

  + Cytoreduction + antiplatelet agents

5.26

2.47–11.2

<.0001

1.16

0.60–2.22

0.662

  + JAK2V617F homo

5.41

2.53–11.6

<.0001

1.11

0.58–2.15

0.750

  1. OR odds ratio, CI confidence interval, p p value, PV polycythemia vera, ASA acetylsalicylic acid
  2. aReference categories: hs-CRP <0.8 mg/L; PTX3 <4.8 ng/mL
  3. The variables resulted statistically significant are reported in italicized style
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us